Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility.
Vergeer M, Boekholdt SM, Sandhu MS, Ricketts SL, Wareham NJ, Brown MJ, de Faire U, Leander K, Gigante B, Kavousi M, Hofman A, Uitterlinden AG, van Duijn CM, Witteman JC, Jukema JW, Schadt EE, van der Schoot E, Kastelein JJ, Khaw KT, Dullaart RP, van Tol A, Trip MD, Dallinga-Thie GM. Vergeer M, et al. Circulation. 2010 Aug 3;122(5):470-7. doi: 10.1161/CIRCULATIONAHA.109.912519. Epub 2010 Jul 19. Circulation. 2010. PMID: 20644014
The value of HDL genetics.
Holleboom AG, Vergeer M, Hovingh GK, Kastelein JJ, Kuivenhoven JA. Holleboom AG, et al. Among authors: vergeer m. Curr Opin Lipidol. 2008 Aug;19(4):385-94. doi: 10.1097/MOL.0b013e328306a043. Curr Opin Lipidol. 2008. PMID: 18607186 Review.
Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, Grobbee DE, Visseren FL, Stalenhoef AF, Stroes ES, Kastelein JJ. Vergeer M, et al. Circulation. 2008 Dec 9;118(24):2515-22. doi: 10.1161/CIRCULATIONAHA.108.772665. Epub 2008 Nov 24. Circulation. 2008. PMID: 19029469 Clinical Trial.
C-reactive protein is a mediator of cardiovascular disease.
Bisoendial RJ, Boekholdt SM, Vergeer M, Stroes ES, Kastelein JJ. Bisoendial RJ, et al. Among authors: vergeer m. Eur Heart J. 2010 Sep;31(17):2087-91. doi: 10.1093/eurheartj/ehq238. Epub 2010 Aug 3. Eur Heart J. 2010. PMID: 20685682 Review.
Plasma levels of lecithin:cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective case-control analysis nested in the EPIC-Norfolk population study.
Holleboom AG, Kuivenhoven JA, Vergeer M, Hovingh GK, van Miert JN, Wareham NJ, Kastelein JJ, Khaw KT, Boekholdt SM. Holleboom AG, et al. Among authors: vergeer m. J Lipid Res. 2010 Feb;51(2):416-21. doi: 10.1194/P900038-JLR200. Epub 2009 Aug 11. J Lipid Res. 2010. PMID: 19671930 Free PMC article.
92 results